J. Larsen

Potent and orally bioavailable noncysteine-containing inhibitors of protein farnesyltransferase.

S. Ng, D. Augeri, P. Kovar, 1999, Bioorganic & medicinal chemistry letters.

Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity.

A. Ritzén, C. Mølck, P. Lovato, 2020, Journal of medicinal chemistry.

Discovery of a series of cyclohexylethylamine-containing protein farnesyltransferase inhibitors exhibiting potent cellular activity.

S. Ng, S. Rosenberg, H. Sham, 1999, Journal of medicinal chemistry.

Evaluating Dermal Pharmacokinetics and Pharmacodymanic Effect of Soft Topical PDE4 Inhibitors: Open Flow Microperfusion and Skin Biopsies

F. Sinner, Fredrik Johansson, T. Birngruber, 2020, Pharmaceutical Research.

Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase.

S. Ng, D. Augeri, S. Rosenberg, 1998, Journal of medicinal chemistry.

Discovery and Early Clinical Development of Isobutyl 1-[8-Methoxy-5-(1-oxo-3H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxylate (LEO 39652), a Novel "Dual-Soft" PDE4 Inhibitor for Topical Treatment of Atopic Dermatitis.

H. Pettersson, T. Skak-Nielsen, M. D. Sørensen, 2020, Journal of medicinal chemistry.

Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis.

A. Vinggaard, M. D. Sørensen, J. Felding, 2014, Journal of medicinal chemistry.